We are live on ! Find out more
INZY

Inozyme Pharma
INZY

Delisted

INZY was delisted on the 30th of June, 2025.

Back to rankings

80 hedge funds and large institutions have $214M invested in Inozyme Pharma in 2023 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 42 increasing their positions, 15 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,341% more call options, than puts

Call options by funds: $1.44M | Put options by funds: $100K

180% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 15

44% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 9

4% more funds holding

Funds holding: 77 → 80 (+3)

2.34% more ownership

Funds ownership: 78.93% → 81.27% (+2.3%)

4% more capital invested

Capital invested by funds: $205M → $214M (+$9.18M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
80
Holders Change
+3
Holders Change %
+3.9%
% of All Funds
1.17%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
13
Increased
42
Reduced
15
Closed
9
Calls
$1.44M
Puts
$100K
Net Calls
+$1.34M
Net Calls Change
+$891K

Top Buyers

Rank Fund Capital Flow
1
BOCH
Blue Owl Capital Holdings
New York
+$4.51M
2
BlackRock
BlackRock
New York
+$2.85M
3
AAA
Affinity Asset Advisors
New York
+$1.8M
4
SFM
Sphera Funds Management
Israel
+$1.17M
5
Goldman Sachs
Goldman Sachs
New York
+$1.1M

Top Sellers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
-$3.2M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.94M
3
Millennium Management
Millennium Management
New York
-$1.48M
4
SSA
Schonfeld Strategic Advisors
New York
-$722K
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$685K
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$23.6M – – –
PBPIA
2
Pivotal bioVenture Partners Investment Advisor
California
$19.1M – – –
SI
3
Sofinnova Investments
California
$18.2M – – –
RSCM
4
Rock Springs Capital Management
Maryland
$15.7M – – –
SC
5
Samlyn Capital
New York
$14.4M +$452K +127,350 +4%
EAM
6
Eventide Asset Management
Massachusetts
$13.5M +$195K +54,837 +2%
BlackRock
7
BlackRock
New York
$13M +$2.85M +802,588 +36%
NMC
8
NEA Management Company
Maryland
$10.4M – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$10.2M +$387K +108,937 +5%
Fidelity Investments
10
Fidelity Investments
Massachusetts
$9.68M -$685K -192,926 -8%
AAA
11
Affinity Asset Advisors
New York
$8.03M +$1.8M +505,950 +37%
SFM
12
Sphera Funds Management
Israel
$6.66M +$1.17M +328,000 +27%
SB
13
Samsara BioCapital
California
$6.66M – – –
BOCH
14
Blue Owl Capital Holdings
New York
$5.41M +$4.51M +1,270,027 New
Geode Capital Management
15
Geode Capital Management
Massachusetts
$4.4M +$746K +209,893 +26%
Millennium Management
16
Millennium Management
New York
$3.88M -$1.48M -415,406 -31%
State Street
17
State Street
Massachusetts
$3.18M +$420K +118,186 +19%
DMKJ
18
David M. Knott Jr
$2.4M +$393K +110,541 +24%
LCM
19
Laurion Capital Management
New York
$2.37M -$426K -120,000 -18%
Northern Trust
20
Northern Trust
Illinois
$1.81M +$320K +90,060 +27%
OCA
21
Octagon Capital Advisors
New York
$1.7M -$3.2M -900,000 -69%
Goldman Sachs
22
Goldman Sachs
New York
$1.55M +$1.1M +309,484 +574%
MB
23
MPM BioImpact
Massachusetts
$1.38M -$11K -3,108 -1%
WP
24
Woodline Partners
California
$1.28M +$1.07M +300,000 New
KCM
25
Kennedy Capital Management
Missouri
$1.22M +$1.02M +287,537 New
1
2 3 4

INZY Hedge Fund Activity: Q4 2023 in Review

80 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q4 2023, worth a combined $214M — up 4.5% from $205M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new INZY positions and 9 closed out — a net gain of 4 holders — while 42 added to existing stakes and 15 trimmed.

The largest buyer was Blue Owl Capital Holdings, opening a new position worth an estimated $4.51M. The largest seller was Octagon Capital Advisors, cutting an estimated $3.2M.

  • 80 institutional investors held Inozyme Pharma (INZY) as of Q4 2023, up from 77 in Q3 2023.
  • Funds reported $214M of Inozyme Pharma stock for Q4 2023, up 4.5% quarter-over-quarter.
  • 13 funds opened new Inozyme Pharma positions in Q4 2023 and 9 closed out, a net change of +4 holders.
  • The largest Inozyme Pharma buyer in Q4 2023 was Blue Owl Capital Holdings, an estimated $4.51M added.
  • The largest Inozyme Pharma seller in Q4 2023 was Octagon Capital Advisors, an estimated $3.2M sold.

Based on aggregated 13F filings for Q4 2023.